Advertisement

Topics

Debiopharm Group Company Profile

23:38 EDT 21st June 2018 | BioPortfolio

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect on HCV replication both in vitro and in vivo. Debio 025 has excellent antiviral activity against a broad range of genotypes (1, 2, 3 and 4); a high barrier to the development of resistance; and the possibility for once daily dosing. It is expected to have a superior safety and efficacy profile to standard of care, and to be efficacious in patients not responding to the standard treatment.


News Articles [409 Associated News Articles listed on BioPortfolio]

Debiopharm continues fight against antibiotic resistance

Debiopharm Group invests in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics

Debiopharm poursuit le combat contre les résistances aux antibiotiques avec un investissement ...

Debiopharm Group™ annonce un investissement dans les antibiotiques avec l'acquisition d'une part minoritaire de la société ABAC Therapeutics Inc. Cette prise de participation par le Read more....

Series A lands €16mm for ABAC Therapeutics

Antibiotics developer ABAC Therapeutics raised €16mm ($19.8mm) in its Series A financing led by Pontifax, which was joined by Global Health Science Fund (formed by Quark Venture and GF Securities), ...

Biopharm group continues efforts in fight against antibiotic resistance through investment

Debiopharm Group, international biopharmaceutical group, has continued its efforts in the fight against antibiotic resistance by investing in antibiotic development through acquiring a minority stake ...

Debiopharm Strengthens Compliance, Clinical Trial Oversight With Veeva Vault eTMF

Clinical Informatics News Brief | Veeva Systems announced that Debiopharm selected Veeva Vault eTMF to improve oversight across its trial master file processes and work closely with contract rese...

ABAC Therapeutics raises 16 million euros from investors including Debiopharm

Spain-based ABAC Therapeutics, a leader in pathogen-specific antibiotics, announced today the closing…

Debiopharm International SA Strengthens Compliance and Clinical Trial Oversight with Veeva Vault eTMF

Global biopharmaceutical company enables real-time inspection readiness and improves CRO collaboration Veeva Systems (NYSE: VEEV) announced today that

Debiopharm Group Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

SummaryDebiopharm Group Debiopharm is a pharmaceutical company that develops biologics and small molecule drug candidates targeted at unmet medical needs. The company provides products portfolio such ...

PubMed Articles [1807 Associated PubMed Articles listed on BioPortfolio]

Group Influences on Engaging Self-Control: Children Delay Gratification and Value It More When Their In-Group Delays and Their Out-Group Doesn't.

Self-control emerges in a rich sociocultural context. Do group norms around self-control influence the degree to which children use it? We tested this possibility by assigning 3- to 5-year-old childre...

An Examination of Group Size and Valence in Delay Discounting of Shared Outcomes.

Previous research has examined delay discounting in a group context, where the outcomes are shared with others. These studies indicate shallow delay discounting in a group context compared to an indiv...

Ameliorating effects of tempol on methotrexate-induced liver injury in rats.

Methotrexate (MTX) is used in the treatment of certain types of cancers and chronic inflammatory illnesses, although the clinical use of MTX is limited due to its adverse effects, the most common of w...

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Gro...

Nephroprotective Effect of Zingerone against CCl-Induced Renal Toxicity in Swiss Albino Mice: Molecular Mechanism.

The protective effects of Zingerone against CCl induced nephrotoxicity in Swiss albino mice via modulation of metabolizing enzyme, oxidative stress, inflammatory cytokines, and apoptosis. The biochemi...

Clinical Trials [3703 Associated Clinical Trials listed on BioPortfolio]

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

the Influence of Sleep Improvement Through Different Methods on Patients in ICU

In the research, we enroll 120 postoperative patients in the ICU and they will be assigned to four group: the eye patch group, the Dexmedetomidine(DEX) group, the eye patch+DEX group and t...

Companies [1619 Associated Companies listed on BioPortfolio]

The Debiopharm Group

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-l...

Debiopharm Galenic Unit

Debiopharm, Debiovision, Debioinnovation, Debio R.P. and Debioclinic form an established group of five complementary and synergistic companies. Together, they provide drug development expertise and kn...

Debiopharm Group

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect o...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

More Information about "Debiopharm Group" on BioPortfolio

We have published hundreds of Debiopharm Group news stories on BioPortfolio along with dozens of Debiopharm Group Clinical Trials and PubMed Articles about Debiopharm Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Debiopharm Group Companies in our database. You can also find out about relevant Debiopharm Group Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record